Core Viewpoint - The article discusses the lifting of restrictions on the shares of Jiangsu Lanfeng Bio-chemical Co., Ltd. following a major asset restructuring, detailing the compliance of shareholders with their commitments and the financial implications of this event [1][7]. Summary by Sections 1. Basic Situation of Restricted Shares - Jiangsu Lanfeng Bio-chemical Co., Ltd. completed a major asset restructuring by acquiring 100% equity of Shaanxi Ark Pharmaceutical Co., Ltd. through a combination of issuing shares and cash payments, with the new shares being registered as restricted shares [1]. 2. Shareholders' Commitments and Compliance - The shareholders applying for the lifting of restrictions, Ren Wenbin and Chen Jing, made commitments regarding the transfer of shares based on the duration of their asset ownership, with specific percentages of shares allowed for transfer at different time intervals [2][3]. - Both shareholders adhered to their commitments during the lock-up period and have not transferred their restricted shares [3]. 3. Performance Compensation Agreement - The performance compensation agreement stipulated that if Ark Pharmaceutical's net profit fell below certain thresholds for the years 2015, 2016, and 2017, the shareholders would compensate Jiangsu Lanfeng Bio-chemical in cash or shares [3]. - The shareholders fulfilled their compensation obligations for the years 2015 and 2016, but not for 2017, leading to a total compensation amount of 60.53 million yuan [3]. 4. Legal Proceedings and Compensation Payment - Jiangsu Lanfeng Bio-chemical filed a lawsuit against the shareholders for overdue performance compensation, resulting in a court ruling that required Ren Wenbin to pay 2.9561 million yuan and Chen Jing to pay 1.0749 million yuan, both with penalties [4]. - The company has received all compensation payments from the shareholders, fulfilling their obligations [4]. 5. Details of Restricted Shares Lifting - The lifting of restrictions on the shares will allow 1,339,746 shares to be listed for trading, which represents 0.357% of the company's total shares [4][6]. - The shares will become tradable on September 5, 2025 [4]. 6. Financial Advisor's Opinion - The independent financial advisor confirmed that the shareholders complied with their commitments and that the lifting of restrictions aligns with relevant laws and regulations, ensuring accurate and complete disclosure of information by Jiangsu Lanfeng Bio-chemical [7].

江苏蓝丰生物化工股份有限公司 关于非公开发行股份上市流通的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 特别提示： 1、本次解除限售股份为江苏蓝丰生物化工股份有限公司（以下简称"公司"） 2015年度并购陕西方舟制药有限公司（以下简称"方舟制药"）非公开发行A股 股票，本次解除限售股份的数量为1,339,746股，占公司总股本的0.357%； 2、本次解除限售股份上市流通日为2025年9月5日。 证券代码：002513 证券简称：蓝丰生化 公告编号：2025-042 一、公司非公开发行股份概况及股本变化情况 2015年11月20日，中国证券监督管理委员会（以下简称"中国证监会"）下 发《关于核准江苏蓝丰生物化工股份有限公司向王宇等发行股份购买资产并募集 配套资金的批复》（证监许可[2015]2689号），公司通过发行股份及支付现金相 结合的方式向陕西方舟制药有限公司全体股东购买其持有的方舟制药100.00%股 权。公司完成上述非公开发行股份购买资产并募集配套资金相应股份登记手续， 取得中国证券登记结算有限责任公司深圳分公司出具的《股份登记申请受理确 ...

西部证券股份有限公司 关于江苏蓝丰生物化工股份有限公司 （二）本次申请解除限售股份股东作出的承诺情况 1、限售期承诺已经履行完毕 任文彬、陈靖承诺，截至其取得本次交易对价股份时，其用于认购股份的资 产持续拥有权益的时间不足 12 个月的，该部分资产认购的本公司股份自认购股 份上市之日起 36 个月内不转让；其余资产认购的本公司股份自认购股份上市之 日起 12 个月内不转让。 发行股份及支付现金购买资产并募集配套资金暨关联交易 之限售股解禁的核查意见 西部证券股份有限公司（以下简称"西部证券"、"本独立财务顾问"）作 为江苏蓝丰生物化工股份有限公司（以下简称"蓝丰生化"、"公司"或"上市 公司"）2015 年发行股份及支付现金购买资产并募集配套资金暨关联交易（以 下简称"重大资产重组"）之独立财务顾问，根据《中华人民共和国公司法》《中 华人民共和国证券法》《上市公司重大资产重组管理办法》、《深圳证券交易所 股票上市规则》等有关法律法规和规范性文件要求，对上市公司本次限售股份解 除限售上市流通事项进行了核查，具体情况如下： 一、公司本次限售股份取得的基本情况 2015 年 11 月 20 日，中国证券监督管理委员 ...

Financial Performance - The company reported a total revenue of 1.196 billion yuan for the first half of 2025, representing a year-on-year increase of 40.89% [1] - The net profit attributable to shareholders was -44.779 million yuan, showing a year-on-year improvement of 67.87% [1] - In Q2 2025, the revenue reached 652 million yuan, up 38.5% year-on-year, while the net profit attributable to shareholders was -22.624 million yuan, an increase of 79.22% year-on-year [1] Profitability Metrics - The gross margin improved to 2.76%, with a year-on-year increase of 213.27%, while the net margin was -5.36%, reflecting a year-on-year increase of 74.35% [1] - The total of selling, administrative, and financial expenses was 81.677 million yuan, accounting for 6.83% of revenue, a decrease of 31.96% year-on-year [1] Shareholder Metrics - The earnings per share (EPS) improved to -0.12 yuan, a year-on-year increase of 69.79% [1] - The net asset per share was -0.02 yuan, showing a year-on-year increase of 94.09% [1] - The operating cash flow per share was -0.36 yuan, a significant decrease of 295.05% year-on-year [1] Historical Performance - The company has a median Return on Invested Capital (ROIC) of -24.19% over the past decade, with the worst year being 2022 at -51.19% [3] - The company has reported losses in 8 out of 14 annual reports since its listing, indicating a generally poor financial history [3] Cash Flow and Financial Health - The cash flow situation is concerning, with cash and cash equivalents to current liabilities ratio at 38.1% and a negative average operating cash flow to current liabilities ratio over the past three years [3] - The company has faced challenges with accounts receivable, as indicated by negative net profit attributable to shareholders in annual reports [3]

（记者 王晓波） 每经头条（nbdtoutiao）——世界首例基因编辑猪肺成功移植人体 对话主要参与者：距离临床应用还有 多远？ 每经AI快讯，蓝丰生化8月28日发布公告称，截至目前，公司及子公司的对外担保额度总额为30亿元， 占公司2024年度经审计的归属于上市公司股东净资产的9220.31%，均为公司对合并报表内子公司的担 保；截至目前，公司对外担保余额约为6.58亿元，占公司最近一期经审计公司净资产的2023.58%，其 中，公司对合并报表外单位提供的担保余额为2620万元，占公司最近一期经审计公司净资产的 80.52%，公司对合并报表内单位提供的担保余额约为6.32亿元，占公司最近一期经审计公司净资产的 1943.05%。 ...

Group 1 - The company did not distribute cash dividends, issue bonus shares, or increase capital from reserves during the reporting period [2] - The company held its 25th meeting of the 7th Board of Directors on August 27, 2025, via communication voting, with all 8 directors present [6][9] - The Board approved the 2025 semi-annual report and its summary, confirming that the report's preparation complies with legal regulations and accurately reflects the company's situation [7][8] Group 2 - The company plans to provide guarantees for its subsidiary, Anhui Xuhe New Energy Technology Co., Ltd., to ensure stable cooperation with suppliers, with a guarantee amount exceeding 100% of the company's latest audited net assets [24][25] - The total amount of guarantees provided by the company and its subsidiaries is 3 billion, which is 9,220.31% of the company's audited net assets for 2024 [33] - The independent directors unanimously agreed that the guarantee for the subsidiary aligns with legal regulations and will not adversely affect the company or its shareholders [33]

Core Insights - The company reported a revenue of 1.196 billion yuan for the first half of 2025, representing a year-on-year growth of 40.89% [1] - The net profit attributable to shareholders was a loss of 44.779 million yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of 46.5636 million yuan [1] - The basic earnings per share were -0.1193 yuan [1]

江苏蓝丰生物化工股份有限公司 董事、高级管理人员离职管理制度 第一章 总则 第一条 为规范江苏蓝丰生物化工股份有限公司（以下简称"公司"）董事、 高级管理人员离职相关事宜，确保公司治理结构的稳定性和连续性，维护公司及 股东的合法权益，公司根据《中华人民共和国公司法》《中华人民共和国证券法》 《深圳证券交易所股票上市规则》等法律法规、规范性文件及《公司章程》的有 关规定，结合公司实际情况，制定本制度。 第二条 本制度适用于公司董事（含独立董事）、高级管理人员因任期届满、 辞职、被解除职务或其他原因离职的情形。 第二章 离职情形与程序 第三条 公司董事和高级管理人员可以在任期届满以前辞职，董事和高级管 理人员辞职应当向公司提交书面辞职报告，辞职报告中应说明辞职原因，公司收 到辞职报告之日辞职生效，公司将在 2 个交易日内披露有关情况。 第四条 如存在下列情形，在改选出的董事就任前，原董事仍应当依照法律、 行政法规、部门规章和《公司章程》的规定，继续履行董事职责，但存在相关法 规另有规定的除外： （一）董事任期届满未及时改选，或者董事在任期内辞任导致董事会成员低 于法定最低人数； （二）审计委员会成员辞任导致审计委 ...

江苏蓝丰生物化工股份有限公司 互动易平台信息发布及回复内部审核制度 第一章 总则 第一条 为规范江苏蓝丰生物化工股份有限公司（以下简称"公司"）互动 易平台信息发布和回复的管理，建立公司与投资者的良好沟通机制，提升公司 治理水平，根据《上市公司信息披露管理办法》《上市公司投资者关系管理工 作指引》《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监 管指引第 1 号——主板上市公司规范运作》等有关法律、法规、规范性文件和 《公司章程》的规定，结合公司的实际情况，特制定本制度。 第二条 本制度所称"互动易平台"，是指深圳证券交易所为上市公司与投 资者之间搭建的自愿性、交互式信息发布和进行投资者关系管理的综合性网站 平台。 第二章 总体要求 第十条 公司在互动易平台发布信息及对涉及市场热点概念、敏感事项问题 进行答复时，应当谨慎、客观、具有事实依据，不得利用互动易平台迎合市场 热点或者与市场热点不当关联，不得故意夸大相关事项对公司生产经营、研发 创新、采购销售、重大合同、战略合作、发展规划以及行业竞争等方面的影响， 不当影响公司股票及其衍生品种价格。 第十一条 公司在互动易平台发布信息或回复投资者提问时， ...

第一条 为规范江苏蓝丰生物化工股份有限公司（以下简称"公司"）信息 披露暂缓与豁免行为，确保公司及相关信息披露义务人依法合规地履行信息披露 义务，有效保护投资者的合法权益，根据《上市公司信息披露管理办法》《上市 公司信息披露暂缓与豁免管理规定》《深圳证券交易所股票上市规则》《深圳证 券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律、法 规、规范性文件及《公司章程》《信息披露管理制度》的有关规定，结合公司的 实际情况，特制定本制度。 第二条 公司及相关信息披露义务人按照《上市公司信息披露暂缓与豁免管 理规定》《深圳证券交易所股票上市规则》及深圳证券交易所其他相关业务规则 的规定，办理信息披露暂缓、豁免业务的，适用本制度。 第三条 公司及相关信息披露义务人应当真实、准确、完整、及时、公平地 披露信息，不得滥用暂缓或者豁免披露规避信息披露义务、误导投资者，不得实 施内幕交易、操纵市场等违法行为。 第二章 信息披露暂缓与豁免的适用情形 第四条 公司及相关信息披露义务人有确实充分的证据证明拟披露的信息涉 及国家秘密或者其他因披露可能导致违反国家保密规定、管理要求的事项（以下 统称"国家秘密"），依 ...